MedAlliance

GENEVA, Sept. 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon (SELUTION SLR), versus any limus drug-eluting stent (DES). MedAlliance Announces Enrollment … Read more

GENÈVE, 31 mai 2023 /PRNewswire/ — Les résultats à 12 mois de l’étude SELUTION SFA ont été présentés lors de la conférence Japan Endovascular Treatment (JET) à Tokyo. L’objectif de cette étude était d’évaluer la sécurité et l’efficacité de SELUTION SLR™, le nouveau ballon à élution de sirolimus de MedAlliance, pour le traitement endovasculaire des lésions … Read more

GENEBRA, 31 de maio de 2023 /PRNewswire/ — Os resultados de 12 meses do estudo SELUTION SFA foram apresentados na Japan Endovascular Treatment (JET) Conference, em Tóquio. O objetivo deste estudo foi o de avaliar a segurança e eficácia do SELUTION SLR™, um balão eluidor de sirolimus inovador da MedAlliance, para tratamento endovascular de lesões de-novo … Read more

GINEBRA, 31 de mayo de 2023 /PRNewswire/ — Los resultados de 12 meses del ensayo SELUTION SFA se presentaron en la Conferencia de Tratamiento Endovascular de Japón (JET) en Tokio. El objetivo de este estudio fue evaluar la seguridad y la eficacia de SELUTION SLR™, el novedoso balón liberador de sirolimus de MedAlliance, para el tratamiento … Read more

GENEVA, May 31, 2023 /PRNewswire/ — 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for endovascular therapy of de novo and non-stented restenotic lesions in the … Read more